JPRN-UMIN000017874已完成未知
The safety and feasibility of inhaled amikacin for treatment of refractory chronic lower respiratory tract infections - Inhaled amikacin for treatment of refractory chronic lower respiratory tract infections
Center for Infectious Diseases and Infection Control, Keio University School of Medicine0 个研究点目标入组 30 人开始时间: 2015年6月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional,observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Drug allergy of amikacin
研究者
相似试验
招募中
Unknown
Effect of inhaled Amikacin and Colistin in prevention of pneumoniaIRCT20201015049030N3Tehran University of Medical Sciences126
招募中
不适用
Inhaled Amikacin for Ventilator Associated Pneumonia (VAP)Kidney DiseasePACTR201909502649249Faculty of Medicine Alexandria University45
已完成
不适用
Nebulized Amikacin Versus Intravenous Amikacin in the Treatment of Nosocomial PneumoniaPneumoniaNCT02728518National Heart Institute, Egypt133
进行中（未招募）
不适用
Safety and tolerability study of SLIT(TM) Amikacin 500 mg once daily for 14 days by inhalation in cystic fibrosis study subjects chronically infected with Pseudomonas aeruginosa. - NACystic FibrosisEUCTR2005-004899-21-BETransave, Inc.15
招募中
3 期
Evaluation of the efficacy and safety of inhaled magnesium sulfate in combination with standard treatment in Covid-19 patientsCovid-19.COVID-19, virus identifiedU07.1IRCT20191211045691N1ational Research Institute of Tuberculosis and Lung Diseases(NRITLD), Masih Daneshvari Hospital100